PFE | Pfizer Inc. Stock Overview

(Stock Exchange: NYSE)

Day's Range	24.65 - 25.10
52 Week Range	24.48 - 31.54
Beta	0.45
Implied Volatility	30.50%
IV Rank	73.69%
Day's Volume	40,569,908
Average Volume	36,004,200
Shares Outstanding	5,666,990,000
Market Cap	141,334,730,600
Sector	Healthcare
Industry	Drug Manufacturers - General
IPO Date	1972-06-01

Valuation
Profitability
Growth
Health
P/E Ratio	33.25
Forward P/E Ratio	11.74
EPS	0.75
1YR Price Target	32.50
Dividend Yield	6.69%
Dividend Per Share	1.67
Dividend ExDate	2024-01-25
Dividend PayDate	2024-03-01
Employees	88,000
Country	USA
Website	PFE

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.

PFE's peers: ABBV, AMGN, AZN, BIIB, BMY, GILD, JNJ, LLY, MRK, NVS, OGN

*Chart delayed

Analyzing fundamentals for PFE we got that it has average fundamentals where Valuation is considered to be undervalued, Profitability is unacceptably poor, Growth is exceptionally good and Health is weak. For more detailed analysis please see PFE Fundamentals page.

Watching at PFE technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on PFE Technicals page.